Wearable Injectors Market size was valued at USD 6.16 billion in 2022 and is poised to grow at a CAGR of 12.0% from 2023-2029. Wearable Injectors are the drug delivery devices are technologically designed to deliver a large volume drugs to the patients for long durations. Wearable Injectors Market are also called as patch pumps or patch injectors. These injectors are evolved from the traditional syringes, and are designed to make the treatment easier with its single-step delivery mechanism. The device also helps to control the disease in patients and delivers the drug faster and safer manner in the body through parenteral route. These injectors have opened the door of hassle free medication administration for the patients suffering from cancer, cardiovascular diseases, auto-immune diseases, and diabetes. Wearable injectors are user friendly and reduce the need of multiple painful injections and the number of hospital visits. The COVID-19 pandemic's uncertainty has influenced demand for various therapeutics and wearable drug delivery technologies. Healthcare systems around the world made steps to postpone treatments for diseases like cancer in order to prevent the spread of the infection and safeguard high-risk patients from becoming infected. The dangers for patients receiving care grew as the pandemic progressed. Hospitals, which serve the bulk of patients, also became high-risk areas during the epidemic. To address these issues and provide appropriate care to patients suffering from various ailments, a movement from hospital-based care to home-based care has occurred. As a result of the pandemic, telemedicine and homecare are becoming more popular. As a result, healthcare delivery has shifted from hospitals and clinics to home care settings. In the next years, this is projected to generate considerable growth potential for industry players. Cancer patient have discovered the critical benefits of wearable injectors, such as a reduction in disease progression and suffering, which has resulted in a major surge in their acceptance across the healthcare business. The On-body Injector is typically inserted on the stomach or behind the arm. It is normally administered by a nurse on the last day of each chemotherapy cycle. As a result, one of the key market drivers is the rise in the occurrence of cancer and heart disorders.
Wearable Injectors Market Key Developments:
Fastest Growing Market
The growing prevalence of diseases such as diabetes, cardiovascular diseases, cancer, and autoimmune diseases are the major factors expected to drive the global wearable injectors market. Moreover, advancements in technology along with tracking devices, advantages over traditional devices for administering large dose volumes driving the adoption of wearable injectors. Benefits of these devices over other drug delivery devices such as prefilled syringe is that wearable injectors limits the number of subcutaneous injections and reduces the dosing frequency with an acceptable pain that eventually results in improved patient compliance during the course of patient treatment. Furthermore, growing demand for less or painless devices is expected to fuel the growth of the wearable injectors market over the forecast period. However, poor adoption in under developed countries and stringent regulatory approvals may hinder the growth of global wearable injectors market.
The key segments covered in the wearable injectors market are: by type, technology, therapy, end-users and geography
The wearable injectors market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The wearable injectors market key players are: Amgen (U.S.), Medtronic (Ireland), Insulet Corporation (U.S.), Tandem Diabetes Care (U.S.), Dickinson and Company (U.S.)
Table of Content
Market Opportunity Analysis
Market Opportunity Analysis